CTNM
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ · Healthcare · Biotechnology · US
$16.70
−4.95%Jun 30, 2026, 20:05 UTC
Contineum Therapeutics published a manuscript in the Journal of Medicinal Chemistry describing the discovery of its potential best-in-class LPAR1 antagonist PIPE-791.
Source: